Christopher A. Simon

Christopher A. Simon

President and Chief Executive OfficeratHaemonetics· In proxies 2021–2025

Pay in FY2023+23% from the year before

Christopher A. Simon was paid $10.7M in FY2023 (Apr), up 23%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Haemonetics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. HaemoneticsPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrNo stock prices for these years
  2. AdvaMedPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • HaemoneticsDirector · 9 yr on the boardNot independentAudit—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?